Hello again, and welcome back. Welcome to Peter Meintjes, Chief Executive Officer of Pacific Edge. Thanks for joining us, Peter. Peter is currently online, and we are just waiting for him to come through. He is going to be with us in just a second.
Yeah, delighted to be here. How are you doing?
There he is. Good on you, Peter. Oh, just panic relief. Pacific Edge is a diagnostic company with a single assay known as Cxbladder to risk- stratify men with suspected bladder cancer. For any blokes out there who have undergone a cystoscopy only to find their result has come back negative, this test will be music to your ears. The assay now requires patients to provide a urine sample, and the rest of the work is done in the lab. While this test is not definitive, it provides a very high level of predictive value, particularly if the test comes back as negative. Most importantly, in recent weeks, there have been crucial updates to the Medicare reimbursement policy in the U.S., with the key point being that Cxbladder Triage and Triage+ are confirmed as covered for intermediate-risk microhematuria patients, which is great news.
The company estimates this may open up a market of up to 1.1 million testing opportunities per year. Peter, thanks again for joining us today. This opportunity sounds pretty amazing, and I am really looking forward to hearing your presentation. Welcome.
Excellent. Thank you very much. Delighted to dive in.
Yeah, and we'll come back for some questions at the conclusion of your slides.
Perfect. All right, everybody. My name is Dr. Peter Meintjes, CEO of Pacific Edge. This presentation has been uploaded to the ASX, and there is an important disclaimer associated with the information being presented today. I wanted to give you a quick introduction to Pacific Edge. Bladder cancer is a significant global healthcare challenge that Pacific Edge is tackling. As mentioned in the intro, the standard of care is a cystoscopy, which is a highly invasive and uncomfortable procedure in which a camera is inserted into the urethra to go and visually inspect the lining of the bladder wall. We do this to patients because bladder cancer is the single costliest cancer to treat on a per-patient basis. It is the sixth most common cancer in men.
For those unfortunate enough to have had bladder cancer, there is a 50% chance that you will have it again, even after the tumor has been removed. Whether it is primary detection or surveillance of a prior tumor, the procedure is the same, a cystoscopy. It's invasive and uncomfortable. It's costly, low- yield, and there's also quite a lot of variation between different urologists in how they visualize the bladder. Our solution solves all of that. It is Cxbladder, and our patients just pee in a cup. It is a urine test with 99.4% negative predictive value, and it has earned a Grade A rating from the American Urological Association. It solves a range of different problems, but importantly, it can be collected privately in the clinic or in your own home, so there is no procedure, no discomfort.
With that very high negative predictive value, it rules out cancer, leaving cystoscopy only necessary for those who need it. Overall, it reduces the cost of care within the health systems. I want to talk you through two parts of how patients experience our product. One is the patient journey itself, and the other is how a patient experiences our product. If a patient has hematuria, which is blood in the urine, and in the U.S., which is our primary market, there are greater than 7 million patients presenting with hematuria every year, you then go and see a physician when you've got blood in the urine. The way that we recommend one manages this disease is with Cxbladder Triage+ testing. The goal of that test is to rule out cancer and prioritize patients that need a cystoscopy.
If we cannot rule out bladder cancer and a cystoscopy subsequently confirms that there is bladder cancer, you need a surgical intervention called a transurethral resection of a bladder tumor, which is a mouthful, TURBT. What that really means is that a urologist will go in and cut out that tumor while visualizing it via a cystoscopy, and then the tissue sample is used to determine how serious the disease is, and that determines how regularly you need subsequent cystoscopies to check that the cancer is not coming back. That process is called surveillance, and we also have an alternative to surveillance cystoscopies, and that test is called Cxbladder Monitor, and to be superseded by a test called Surveillance+ . Whether it is Triage+ , Monitor, or Surveillance+ , the patient experience is essentially identical. The example here is for Triage+ .
A patient pees in a cup at the clinic or at home, and the test tube gets inserted into the top of the cup to introduce a stabilizing solution. Once stabilized, that can be shipped anywhere in the world and is stable for up to 11 days. We have labs in New Zealand, and that lab analyzes samples for all of New Zealand, Australia, and Southeast Asia, while we also have a lab in Pennsylvania, in Hershey, where we accept samples from all over the U.S., South America, and Israel. At the conclusion of running our tests through that lab, we provide patients with a testing report, which is shown here. In this case, the patient has a low probability of having bladder cancer with a 0.05 score. How you interpret that score is very important.
If you have a low score like this patient example, that patient does not need continued evaluation for bladder cancer. They do not need a procedure. That is 85% of patients. However, if you are part of the 10% of patients who get intermediate risk on our test report, you then have a 27.7% risk of bladder cancer and need to be evaluated with cystoscopy and with ultrasound. If you have a high score, there is a 75% chance that you as a patient have cancer.
You definitely need cystoscopy. You need to be prioritized because there is a 75% chance you have cancer, and this affects about 6.4% of patients. When you scale this up across an entire healthcare system, this is what you see. 100 patients presenting with microhematuria, the prevalence of bladder cancer is the most serious thing that urologists are worried about for these patients.
However, it is only present in around 5% of those patients. You have to perform 100 cystoscopies to find five patients who actually have cancer. If you look at the alternative view, you could give those 100 patients a Cxbladder Triage+ . 85% of those patients can then avoid the cystoscopy safely. The remaining 15 do need a cystoscopy, and we will find the same five cancers.
This means that there is value to patients because low-risk patients avoid invasive, uncomfortable procedures. Clinicians confidently rule out the patients who do not need it, and clinicians can have confidence in that result with a very high negative predictive value. Hospitals do not have to have as many urologists, and this is an important point because the number of urologists in the U.S. is actually falling. We are not training enough urologists, and not all of the counties actually have one available.
In fact, only 62% of U.S. counties have one. The patient load that urologists are being asked to take is increasing. For payers, there is value as well. When you scale this across the system, the savings are $500 per patient using Medicare average data. How big is the market opportunity? If we just look at the key here for the United States, there are 7 million patients who present with hematuria, of which our serviceable market is all of the microhematuria patients, and we currently have Medicare coverage for the intermediate-risk microhematuria patients. We also have testing opportunities for the 750,000 bladder cancer patients who are living with previous bladder cancer, and that we analyze with Surveillance+ . We estimate the total global market for Cxbladder Triage or Cxbladder products at $10.6 billion on the basis of current pricing and these market opportunities.
As mentioned in the intro, we have had a recent inflection point. Our Medicare coverage in the United States has been finalized. It becomes effective on December 20, and we are the only company that has products that have been covered by this policy, creating a moat around our business. Importantly, both Triage and Triage+ are covered. Triage has a price of $1,057 as of January 1, and Triage+ is priced at $1,328 per test, to create a fantastic revenue growth opportunity, operating leverage, and cash flow. Medicare Advantage is also expected to fall into line once we have Medicare policy, which further boosts our cash flow opportunities, and commercial payers become unlocked with Medicare coverage, expected to drive policy adoption and improve our rate of appeals. Another important point is that this is just the starting point.
We have coverage from Medicare for the intermediate-risk patients, but we are planning to expand coverage to include high-risk patients when the next guideline update happens during 2027. All of the clinical evidence that we are developing at the moment is in service of that objective, to expand the covered indications for Triage+. We are doing that with the DRIVE, AUSSIE, and microDRIVE studies, which will be pooled to show how our test works for microhematuria and gross hematuria. All of those are expected to complete prior to the updated literature review from the AUA. Medicare is just the beginning. By far, the largest opportunity rests within the commercial payers of the United States. However, they are a diverse group, but we are already making inroads.
These are typically late-stage achievements for a company, and we're delighted that we already have so many favorable policies when you combine the various wins with Kaiser Permanente, Blue Cross Blue Shield, Sentara, Geisinger, with the Medicare coverage policy. Importantly, policy is the first step to unlocking all of the revenue potential from commercial payers. We do also need to engage with them for commercial contracts, and so we break that into two stages. We have more policy than we have contracts, but we are working for everywhere where we have policy to further convert that to contracts. The market opportunity looks something like this. There is a 2.8 million addressable microhematuria market, of which 1.14 million is covered by Medicare with intermediate risk, and intermediate risk is broken down into male and female, and it is predominantly a female market.
That necessitates some nuances in the way that we sell. We need to go to female-specific call points. We need to go to earlier in the treatment pathway to advanced practice providers who might be ordering the test. We also break down the market into the 1.68 million of these patients who are seen as part of the integrated delivery networks, and the 1.12 million patients who are seen in private practice. We have different strategies for each of those markets, with strategic selling to the institutions, the IDNs, and with a specialty sales force calling on the urologists in private practice. Our financials will shortly be updated. We actually have a financial results presentation in one week from today, and so these are rather old numbers at this point.
But when we raised capital back in June, we raised NZD 36.1 million to fund the next stage of our commercial operations, and we committed to a burn rate of no more than NZD 2.5 million a month, and at present, we are comfortably under that. We've also advised the market of what a future operations for Pacific Edge could look like, that with new pricing effective in January 1, we only need to reach 55,000 tests per year for Pacific Edge to break even, including the costs associated with the larger sales team to commercialize that.
The various inflection points and catalysts coming up are, number one, Medicare coverage for high-risk microhematuria, so expanding that indication, launching a second product, Surveillance+ , adding gross hematuria for Medicare and outside the U.S., launching a kitted research- use- only version of our tests, launching a kitted IVD version of our tests, and ultimately, a new product outside of bladder cancer. To summarize, and I'm looking forward to your questions, we are the first mover in the market. We are chasing a large global market opportunity. We have a Grade A recommendation from the American Urological Association. We have recently had a key catalyst of Medicare agreeing to cover our tests, Cxbladder Triage and Triage+, and we have favorable economics with increased pricing for legacy products and a price of $1,328 for Triage+. I look forward to your questions.
Thank you, Peter. That was a great run through. Can I just start? I want to track back three or four years ago when Medicare funding came to a very abrupt halt. Can you take a moment to explain what happened at that point and what has changed since then?
Yeah. So look, there is a much longer version of the story, but at that time, Medicare were seeking to change the way they covered cancer diagnostic tests.
Yeah.
Pacific Edge's tests, or Triage and Triage+, are not cancer diagnostic tests. They are hematuria evaluation tests for bladder cancer. They were unfortunately included in that approach, and once that was finalized, we have spent the last 18 months ensuring that hematuria evaluation is understood as being different from cancer diagnosis, and consequently, we now have established medical policy that highlights exactly that.
Okay, so that seems quite definitive. Other than cancer, what are the other causes why one might find blood in the urine?
You could have kidney stones, it could be idiopathic, you could have had a punch in the stomach, it could be benign prostatic hyperplasia. By far the most serious cause is bladder cancer.
Yeah.
When patients are being evaluated by urologists, that is the thing that they are really looking to rule out and say, "We are not worried about you immediately dying of cancer or progressing to cancer and dying.
Okay. The value proposition that you outlined seems very compelling for payers. Tell us about your engagement, not only with Medicare, but with the privates as well.
Yeah, absolutely. There are two prongs to this approach. Some commercial payers do make their own medical policy and then do their own contracting for genetic tests.
Yeah.
Others do not. Where they do create their own policy, we engage directly with the policy team. We provide them with the evidence. We call it a clinical dossier, and that clinical dossier gets reviewed by the policy team. With AUA guidelines and Medicare coverage, we expect there are more favorable reviews to come out of those kinds of payers. The process is almost identical if the payers don't make their own policy. It just goes through what's called a lab benefit manager or a data curator.
We already have favorable LBM policy from a group called Avalon, and that has led to some of the wins we have with Blue Cross Blue Shield of North Carolina, South Carolina, Sentara, and others that are continuing to flow through even over the last week.
I imagine it's a Well, nothing's ever easy in the U.S. healthcare system, but I imagine it's a pretty compelling buy for those people. You can rule out 85% of cystoscopies. That's got to amount to millions of NZD over the course of a year for them.
That's right. Look, there's value to the insurance companies.
Yep
by having to pay for fewer procedures. There is value to the urologists who actually do not. Even though there are cost savings associated with avoiding cystoscopies, there is also the opportunity cost for not performing cystoscopies. Revenue, or sorry, urologists who rely on procedures for revenue actually have. They are able to carry more patients, see more patients, but on average, sicker patients if they are ruling out the healthier patients.
Yeah
with a test like Cxbladder.
Yep.
Consequently, they can actually raise the revenue for their practice by following that kind of clinical pathway.
Just talk briefly about the guidelines, the American Urological Association. Where are they at with the guidelines now? Have they formally adopted this test?
They have. In 2025, they provided a recommendation to use this in appropriately counseled intermediate-risk hematuria patients.
Okay.
They will open up the guideline again for review in mid-2027, three years after the last one closed. We have additional evidence that they are going to be looking at, and we expect them to expand their recommendation and also strengthen the language around that recommendation. If we are able to complete our CREDIBLE clinical trial, which is a clinical utility trial for Triage+, we would have an even stronger argument for even more radical guideline change in support of Cxbladder Triage+.
Okay. Just help me understand this concept of intermediate-risk patients, because the way it was in your presentation, you had two groups of 100 lined up, 85% are negative for the test. How do I understand what is an intermediate-risk patient in that patient group?
That particular diagram or figure is referring to all microhematuria patients, but one could change the label and the process would be identical. If you had 100 intermediate-risk microhematuria patients, the risk of those patients having bladder cancer will be 3%-5%, and consequently, the AUA guidelines recommends cystoscopy.
Okay, we've kind of lost Peter there just for a moment. Hopefully, he comes back in a few seconds. It certainly is a compelling buy case for the payers. If you can rule out, obviously, millions of dollars in costs, that amounts to a pretty compelling improvement in underwriting margin. We're just going to go to a short break and see if we can get Peter back on the line.
Victor, I'm here.
Here he is.
I can still hear you. Apologies for the connection issues.
No, it's all right. I can hear you, Peter. We can proceed.
You're good to. Just let me know where you want to. You're good to start from there.
Okay. All right, we'll resume. We're back on, Peter. Thank you. You were just answering the question about intermediate risk and potentially expanding that label. Continue on.
Yeah, so look, the expansion from intermediate risk to all-risk microhematuria patients will come as a consequence of an update to the AUA guideline.
Yep.
We have already developed all of the evidence necessary for that. We are just in the process of analyzing that data, and we are in the process of publishing that data. All of that will happen within the next nine months, ahead of when we expect the AUA to open up their next updated literature review, which is in June 2027.
Okay, let us talk about your commercialization activities in the U.S. now. Where are you at today? You mentioned that the policy reimbursement policy becomes effective on December 20. Let us talk about the plans for new year. I do not want you to give revenue guidance, but what is your commercialization plan for next year?
Yeah, look, the salespeople have been given a very clear directive, and that is growth is the baseline.
Yep.
Importantly, as an organization in totality, we are not growing top line at all costs. We have to grow responsibly. What that means is we are asking the existing sales team, we are augmenting that with just three or four roles, and we are asking everybody to become more effective, essentially improving the unit economics of operating a sales rep. We want to make that more efficient so that everybody is paying 3x or 4x their cost.
Yep.
As we execute on that, we will look to resume growth at the top line by hiring more and more people. We have a plan to responsibly grow our sales team back, focused on profitability.
Okay. You have the lab up and running in Pennsylvania, I think you said already. So there is no tech transfer, there is no further obstacle to commercialization of this program as we head into fiscal year or calendar year 2027?
Yeah, that is correct. We have been operating Triage+ commercially for quite some time in the lab through the non-coverage.
Yeah.
It has just been more challenging to get paid on every test. Now we expect to get paid on every Medicare test, we expect to get paid on every Medicare Advantage test, and we expect to get paid on an increasing percentage of every commercial test that we run for an intermediate risk microhematuria patients in the U.S.
And just finally, on that issue with Medicare, look, reimbursement is never straightforward. Do you have to go through state by state in order to expand that coverage?
For Medicare coverage, the answer is no. For Medicaid, which makes up a very, very tiny fraction of our business, that is actually state- credentialed.
Yeah.
So we do not view a state-by-state process as particularly important for our business. What is much more important is, your earlier question, is going payer by payer
Yeah
and making sure that we are covered by the different regional payers in their specific states and cities.
Hmm. Okay. Look, that's been a great run through, Peter. Some big events in the not-too-distant future with your rollout of the fully reimbursed test. Thank you for your time this afternoon, and we'll catch up with you again in the not-too-distant future.
Thanks very much, John. Happy to be here.
Good on you. Okay, thank you very much. That was Pacific Edge. We are going to go straight into the presentation for Lumos Diagnostics, and Martyn Jacobs is going to be hosting that. Martyn will also wrap up the day's events. Thank you.